|
|
 |
|
Viewing report
|
|
 |
 |
Vildagliptin (Galvus®, LAF237) - R & D Biopharmaceutical & Pharmaceutical Product Profile
BioPolaris, March 2010, Pages: 2
Vildagliptin (Galvus®, LAF237) - R & D Biopharmaceutical & Pharmaceutical Product Profile.
Vildagliptin (Galvus®, LAF237) is a late-stage R & D therapeutic product.
Sources of Information:
Research data published in this product profile are obtained primarily from companies involved in its development. In addition, the analyst used other available sources of information, including database of the US National Institutes of Health (NIH).
Rarely, and only when necessary, information was based on published scientific articles.
Customers who bought this item also bought
Galvus (Type 2 Diabetes) - Analysis and Forecasts to 2020
DPP IV Inhibitors - Global Strategic Business Report
UNI-rE-4 (rExendin-4) - R & D Biopharmaceutical & Pharmaceutical Product Profile
Alogliptin (SYR-322) - R & D Biopharmaceutical & Pharmaceutical Product Profile
Cetilistat (ATL-962) - R & D Biopharmaceutical & Pharmaceutical Product Profile
IN-105 - R & D Biopharmaceutical & Pharmaceutical Product Profile
Linagliptin (Ondero®, BI 1356) - R & D Biopharmaceutical & Pharmaceutical Product Profile
LY2189265 - R & D Biopharmaceutical & Pharmaceutical Product Profile
Oral-lyn (Oral Recosulin) - R & D Biopharmaceutical & Pharmaceutical Product Profile
Rivoglitazone (CS-011, DE-101) - R & D Biopharmaceutical & Pharmaceutical Product Profile
|
 |
|
|